Senzime signs distribution agreements for the TetraGraph
Senzime has entered exclusive distribution agreements for the commercialization of TetraGraph with Wardray Premise Ltd., who will be the exclusive distributor in the UK and Ireland and LSR Healthcare who will be the exclusive distributor in Australia and New Zealand. Compensation to distributors will be paid on a “per-unit sold” basis, and is in line with current industry compensation, in which there are no guaranteed sales.
Lena Söderström, Senzimes CEO, commented: "Wardray and LSR are ideal partners for several reasons. They have a complementary product portfolio and previously distributed the TOF-Watch, which was recently withdrawn from the market. Additionally, the distributors have the infrastructure and experience needed to make the TetraGraph into a market leader in these countries. Discussions with additional potential partners are in progress, the CE mark is in its final phase and we expect that sales will commence during the first half of 2017."
The TetraGraph is an innovative and user-friendly system for monitoring patients undergoing general anesthesia with muscle relaxant drugs. The system makes it possible to objectively determine the correct dose of muscle relaxants, and helps the clinician determine when the patient is sufficiently recovered to sustain spontaneous breathing. The TetraGraph is intended to easily and precisely monitor the effects of muscle relaxant drugs and their reversal agents and reduce postoperative complications and healthcare costs. The system consists of a portable, hand-held patient monitoring unit and non-invasive disposable sensors.
Every year, over 70 million patients undergo surgery and receive muscle relaxant drugs; research has shown that over 30 percent of patients suffer from postoperative complications if objective neuromuscular monitoring is not used. The TetraGraph is an inexpensive and easy-to-use solution that helps clinicians avoid postoperative complications in their patients.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of $10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication trough the agency of the contact person set out above, on February 9, 2017.